Korean J Med.
2025 Apr;100(2):81-85. 10.3904/kjm.2025.100.2.81.
Diagnosis and Treatment of HER2-Positive Breast Cancer
- Affiliations
-
- 1Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
- KMID: 2566388
- DOI: http://doi.org/10.3904/kjm.2025.100.2.81
Abstract
- Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for approximately 20% of all breast cancer cases. The advent of therapies targeting HER2 has significantly improved the prognosis for HER2-positive breast cancer. Neoadjuvant/adjuvant chemotherapy with HER2-targeted agents is recommended for early and locally advanced breast cancer. The appropriate use of novel HER2-targeted therapies is recommended for metastatic breast. We aimed to examine the diagnosis and personalized treatment for HER2-positive breast cancer.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer
- Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
- HER2-Low Breast Cancer: Now and in the Future
- Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
- Exploring the clinicopathological parameters of HER2 low breast cancers: insights from a retrospective cohort study
